WO1994011026A2
(en)
*
|
1992-11-13 |
1994-05-26 |
Idec Pharmaceuticals Corporation |
Therapeutic application of chimeric and radiolabeled antibodies to human b lymphocyte restricted differentiation antigen for treatment of b cell lymphoma
|
US7744877B2
(en)
*
|
1992-11-13 |
2010-06-29 |
Biogen Idec Inc. |
Expression and use of anti-CD20 Antibodies
|
EP1974747B1
(en)
*
|
1998-08-11 |
2012-06-27 |
Biogen Idec Inc. |
Combination therapies for B-cell lymphomas comprising administration of anti-CD20 antibody
|
MXPA01004649A
(es)
*
|
1998-11-09 |
2002-05-06 |
Idec Pharma Corp |
Tratamiento con anticuerpo quimerico anti-cd20 para pacientes que reciben transplantes de medula osea o celulas madre de sangre periferica.
|
MXPA01004648A
(es)
*
|
1998-11-09 |
2002-05-06 |
Idec Pharma Corp |
Tratamientro de enfermedades hematologicas malignas asociadas con celulas tumorales de la circulacion usando el anticuerpo quimerico anti-cd20.
|
US8557244B1
(en)
|
1999-08-11 |
2013-10-15 |
Biogen Idec Inc. |
Treatment of aggressive non-Hodgkins lymphoma with anti-CD20 antibody
|
US7754208B2
(en)
|
2001-01-17 |
2010-07-13 |
Trubion Pharmaceuticals, Inc. |
Binding domain-immunoglobulin fusion proteins
|
ATE540978T1
(de)
|
2002-10-17 |
2012-01-15 |
Genmab As |
Humane monoklonale antikörper gegen cd20
|
DE10254601A1
(de)
|
2002-11-22 |
2004-06-03 |
Ganymed Pharmaceuticals Ag |
Differentiell in Tumoren exprimierte Genprodukte und deren Verwendung
|
ES2633311T3
(es)
|
2002-12-16 |
2017-09-20 |
Genentech, Inc. |
Variantes de inmunoglobulina y usos de las mismas
|
JP5416338B2
(ja)
*
|
2003-05-09 |
2014-02-12 |
デューク ユニバーシティ |
Cd20特異的抗体およびその使用方法
|
AR044388A1
(es)
*
|
2003-05-20 |
2005-09-07 |
Applied Molecular Evolution |
Moleculas de union a cd20
|
MXPA06002134A
(es)
*
|
2003-08-29 |
2006-05-31 |
Genentech Inc |
Terapia de trastornos oculares.
|
PL2380911T3
(pl)
|
2003-11-05 |
2018-10-31 |
Roche Glycart Ag |
Cząsteczki wiążące antygen o zwiększonym powinowactwie wiązania z receptorem Fc oraz zwiększonej funkcji efektorowej
|
FR2867982B1
(fr)
*
|
2004-03-26 |
2007-07-20 |
Jean Marie Andrieu |
Procede pour amplifier l'activite de vaccins therapeutiques
|
KR20070012408A
(ko)
*
|
2004-04-16 |
2007-01-25 |
제넨테크, 인크. |
B 세포 고갈을 증대시키는 방법
|
EP1745288A2
(en)
*
|
2004-04-16 |
2007-01-24 |
Genentech, Inc. |
Assay for antibodies
|
EP1742660A2
(en)
*
|
2004-04-16 |
2007-01-17 |
Genentech, Inc. |
Treatment of disorders
|
US7850962B2
(en)
*
|
2004-04-20 |
2010-12-14 |
Genmab A/S |
Human monoclonal antibodies against CD20
|
US20050271658A1
(en)
*
|
2004-05-05 |
2005-12-08 |
Genentech, Inc. |
Preventing autoimmune disease
|
DE102004024617A1
(de)
|
2004-05-18 |
2005-12-29 |
Ganymed Pharmaceuticals Ag |
Differentiell in Tumoren exprimierte Genprodukte und deren Verwendung
|
US9228008B2
(en)
|
2004-05-28 |
2016-01-05 |
Idexx Laboratories, Inc. |
Canine anti-CD20 antibodies
|
AR049200A1
(es)
*
|
2004-06-04 |
2006-07-05 |
Genentech Inc |
Metodo para tratar esclerosis multiple con una composicion que contiene un anticuerpo cd20
|
EP1763509B1
(en)
*
|
2004-07-02 |
2018-02-21 |
The Walter And Eliza Hall Institute Of Medical Research |
Alpha-helical mimetics
|
WO2006085967A2
(en)
*
|
2004-07-09 |
2006-08-17 |
Xencor, Inc. |
OPTIMIZED ANTI-CD20 MONOCONAL ANTIBODIES HAVING Fc VARIANTS
|
JP5055603B2
(ja)
|
2004-08-04 |
2012-10-24 |
メントリック・バイオテック・リミテッド・ライアビリティ・カンパニー |
変異Fc領域
|
RU2411956C2
(ru)
*
|
2004-10-05 |
2011-02-20 |
Дженентек, Инк. |
Способ лечения васкулита
|
JO3000B1
(ar)
|
2004-10-20 |
2016-09-05 |
Genentech Inc |
مركبات أجسام مضادة .
|
FR2879204B1
(fr)
|
2004-12-15 |
2007-02-16 |
Lab Francais Du Fractionnement |
Anticorps cytotoxique dirige contre les proliferations hematopoietiques lymphoides de type b.
|
US20080199499A1
(en)
*
|
2005-01-12 |
2008-08-21 |
Proteonova, Inc. |
Method for Making Targeted Therapeutic Agents
|
US10206998B2
(en)
|
2005-01-12 |
2019-02-19 |
Proteonova, Inc. |
Modular targeted therapeutic agents and methods of making same
|
AU2006226733C9
(en)
*
|
2005-03-23 |
2019-03-14 |
Genmab A/S |
Antibodies against CD38 for treatment of multiple myeloma
|
AR053579A1
(es)
*
|
2005-04-15 |
2007-05-09 |
Genentech Inc |
Tratamiento de la enfermedad inflamatoria intestinal (eii)
|
WO2006117910A1
(ja)
|
2005-04-28 |
2006-11-09 |
Mochida Pharmaceutical Co., Ltd. |
抗血小板膜糖蛋白質ⅵモノクローナル抗体
|
JP5224707B2
(ja)
*
|
2005-04-28 |
2013-07-03 |
持田製薬株式会社 |
抗血小板膜糖蛋白質viモノクローナル抗体
|
KR101273829B1
(ko)
|
2005-05-20 |
2013-06-11 |
론자 바이올로직스 피엘씨 |
포유류 숙주 세포에서의 재조합 항체의 고-수준 발현
|
FR2886298A1
(fr)
*
|
2005-05-24 |
2006-12-01 |
Ifremer |
Anticorps ou fragment d'anticorps couple a un agent immunogene
|
JP2008541758A
(ja)
*
|
2005-06-02 |
2008-11-27 |
アストラゼネカ エービー |
Cd20に対する抗体およびその使用
|
CA2615846A1
(en)
|
2005-07-21 |
2007-01-25 |
Genmab A/S |
Potency assays for antibody drug substance binding to an fc receptor
|
DK1912675T3
(da)
|
2005-07-25 |
2014-03-24 |
Emergent Product Dev Seattle |
B-cellereduktion under anvendelse af cd37-specifikke og cd20-specifikke bindingsmolekyler
|
US20090215992A1
(en)
*
|
2005-08-19 |
2009-08-27 |
Chengbin Wu |
Dual variable domain immunoglobulin and uses thereof
|
EP1762575A1
(en)
|
2005-09-12 |
2007-03-14 |
Ganymed Pharmaceuticals AG |
Identification of tumor-associated antigens for diagnosis and therapy
|
MY149159A
(en)
|
2005-11-15 |
2013-07-31 |
Hoffmann La Roche |
Method for treating joint damage
|
US9726673B2
(en)
|
2005-11-23 |
2017-08-08 |
Genentech, Inc. |
Methods and compositions related to B cell assays
|
EP1790664A1
(en)
|
2005-11-24 |
2007-05-30 |
Ganymed Pharmaceuticals AG |
Monoclonal antibodies against claudin-18 for treatment of cancer
|
TWI461436B
(zh)
*
|
2005-11-25 |
2014-11-21 |
Kyowa Hakko Kirin Co Ltd |
人類cd134(ox40)之人類單株抗體及其製造及使用方法
|
EP2359834B1
(en)
|
2006-03-15 |
2016-11-09 |
Alexion Pharmaceuticals, Inc. |
Treatment of paroxysmal nocturnal hemoglobinuria patients by an inhibitor of complement
|
ES2654040T3
(es)
|
2006-03-31 |
2018-02-12 |
Chugai Seiyaku Kabushiki Kaisha |
Método de modificación de anticuerpos para la purificación de anticuerpos biespecíficos
|
TWI390034B
(zh)
*
|
2006-04-06 |
2013-03-21 |
Kyowa Hakko Kirin Co Ltd |
Novel anti-CD98 antibody
|
CN105837690A
(zh)
|
2006-06-12 |
2016-08-10 |
新兴产品开发西雅图有限公司 |
具有效应功能的单链多价结合蛋白
|
CA2656620C
(en)
|
2006-07-04 |
2018-03-13 |
Genmab A/S |
Cd20 binding molecules for the treatment of copd
|
RS59005B1
(sr)
|
2006-09-26 |
2019-08-30 |
Genmab As |
Anti-cd38 plus kortikosteroidi plus nekortikosteroidni hemoterapeutik za tretiranje tumora
|
EA018836B1
(ru)
*
|
2006-10-02 |
2013-11-29 |
Медарекс, Л.Л.К. |
Человеческие антитела, которые связываются с cxcr4, и их применение
|
US9382327B2
(en)
|
2006-10-10 |
2016-07-05 |
Vaccinex, Inc. |
Anti-CD20 antibodies and methods of use
|
NZ577933A
(en)
|
2007-01-22 |
2011-12-22 |
Genentech Inc |
Polyelectrolyte precipitation and purification of antibodies
|
EP1970384A1
(en)
|
2007-03-14 |
2008-09-17 |
Ganymed Pharmaceuticals AG |
Monoclonal antibodies for treatment of cancer
|
PE20090190A1
(es)
*
|
2007-03-23 |
2009-03-22 |
Smithkline Beecham Corp |
Combinacion de anticuerpos anti-cd20 y polipeptidos de il-18
|
US7960139B2
(en)
|
2007-03-23 |
2011-06-14 |
Academia Sinica |
Alkynyl sugar analogs for the labeling and visualization of glycoconjugates in cells
|
ES2667863T3
(es)
*
|
2007-03-29 |
2018-05-14 |
Genmab A/S |
Anticuerpos biespecíficos y métodos de producción de los mismos
|
EP1997832A1
(en)
|
2007-05-29 |
2008-12-03 |
Ganymed Pharmaceuticals AG |
Monoclonal antibodies against Claudin-18 for treatment of cancer
|
RU2009148597A
(ru)
|
2007-05-29 |
2011-07-10 |
Новартис АГ (CH) |
Новые показания к применению при лечении антителами против il-1-бета
|
JP5570974B2
(ja)
|
2007-05-31 |
2014-08-13 |
ゲンマブ エー/エス |
一価ヒト抗体を産生するトランスジェニック動物およびこれらの動物から得ることのできる抗体
|
EP2164873B2
(en)
|
2007-05-31 |
2018-09-12 |
Genmab A/S |
Stable igg4 antibodies
|
UA107557C2
(xx)
|
2007-07-06 |
2015-01-26 |
|
Композиція антитіла офатумумабу
|
ES2527297T3
(es)
|
2007-07-31 |
2015-01-22 |
Regeneron Pharmaceuticals, Inc. |
Anticuerpos humanos para CD20 humano y método para utilizar los mismos
|
AU2008295140A1
(en)
*
|
2007-09-05 |
2009-03-12 |
F. Hoffmann-La Roche Ag |
Combination therapy with type I and type II anti-CD20 antibodies
|
US20090098118A1
(en)
|
2007-10-15 |
2009-04-16 |
Thomas Friess |
Combination therapy of a type ii anti-cd20 antibody with an anti-bcl-2 active agent
|
JP2011500715A
(ja)
|
2007-10-16 |
2011-01-06 |
ザイモジェネティクス, インコーポレイテッド |
自己免疫疾患の治療のためのBLyS阻害剤および抗CD20剤の組合せ
|
WO2009052830A1
(en)
*
|
2007-10-22 |
2009-04-30 |
Genmab A/S |
Novel antibody therapies
|
PE20091434A1
(es)
|
2007-10-30 |
2009-10-17 |
Genentech Inc |
Purificacion de anticuerpos por cromatografia de intercambio cationico
|
EP2231183A2
(en)
*
|
2007-12-21 |
2010-09-29 |
Genentech, Inc. |
Therapy of rituximab-refractory rheumatoid arthritis patients
|
EP2077281A1
(en)
|
2008-01-02 |
2009-07-08 |
Bergen Teknologioverforing AS |
Anti-CD20 antibodies or fragments thereof for the treatment of chronic fatigue syndrome
|
US7914785B2
(en)
|
2008-01-02 |
2011-03-29 |
Bergen Teknologieverforing As |
B-cell depleting agents, like anti-CD20 antibodies or fragments thereof for the treatment of chronic fatigue syndrome
|
NZ587284A
(en)
*
|
2008-03-25 |
2012-05-25 |
Roche Glycart Ag |
Use of a type ii anti-cd20 antibody with increased antibody dependent cellular cytotoxicity (adcc) in combination with cyclophosphamide, vincristine and doxorubicine for treating non-hodgkin' s lymphomas
|
JP6013733B2
(ja)
|
2008-04-11 |
2016-10-25 |
エマージェント プロダクト デベロップメント シアトル, エルエルシー |
Cd37免疫治療薬および二機能性化学療法薬とのその組合せ
|
WO2009134738A1
(en)
*
|
2008-04-29 |
2009-11-05 |
Genentech, Inc. |
Responses to immunizations in rheumatoid arthritis patients treated with a cd20 antibody
|
US8680020B2
(en)
|
2008-07-15 |
2014-03-25 |
Academia Sinica |
Glycan arrays on PTFE-like aluminum coated glass slides and related methods
|
WO2010014784A2
(en)
|
2008-08-01 |
2010-02-04 |
Bristol-Myers Squibb Company |
Combination of anti-ctla4 antibody with diverse therapeutic regimens for the synergistic treatment of proliferative diseases
|
KR102196883B1
(ko)
|
2008-08-14 |
2020-12-30 |
제넨테크, 인크. |
고유 단백질 대체 이온 교환 막 크로마토그래피를 이용한 오염물의 제거 방법
|
EP2684570A1
(en)
|
2008-09-10 |
2014-01-15 |
F. Hoffmann-La Roche AG |
Compositions and methods for the prevention of oxidative degradation of proteins
|
AR073295A1
(es)
|
2008-09-16 |
2010-10-28 |
Genentech Inc |
Metodos para tratar la esclerosis multiple progresiva. articulo de fabricacion.
|
EP2166021A1
(en)
|
2008-09-16 |
2010-03-24 |
Ganymed Pharmaceuticals AG |
Monoclonal antibodies for treatment of cancer
|
WO2010042433A1
(en)
|
2008-10-06 |
2010-04-15 |
Bristol-Myers Squibb Company |
Combination of cd137 antibody and ctla-4 antibody for the treatment of proliferative diseases
|
SG10201610247QA
(en)
|
2008-12-03 |
2017-02-27 |
Genmab As |
Antibody variants having modifications in the constant region
|
WO2010075249A2
(en)
|
2008-12-22 |
2010-07-01 |
Genentech, Inc. |
A method for treating rheumatoid arthritis with b-cell antagonists
|
CA2744670C
(en)
*
|
2009-01-06 |
2018-05-15 |
Ziad Mallat |
A b cell depleting agent for the treatment of atherosclerosis
|
JP2012515217A
(ja)
*
|
2009-01-16 |
2012-07-05 |
グラクソスミスクライン・リミテッド・ライアビリティ・カンパニー |
ベンダムスチンおよび抗−cd20抗体の組合せを用いた癌治療
|
KR102340685B1
(ko)
|
2009-02-20 |
2021-12-17 |
가니메드 파마슈티칼스 게엠베하 |
암의 진단 및 치료를 위한 방법 및 조성물
|
US20100247484A1
(en)
|
2009-03-31 |
2010-09-30 |
Heinrich Barchet |
Combination therapy of an afucosylated antibody and one or more of the cytokines gm csf, m csf and/or il3
|
ES2768990T3
(es)
|
2009-07-20 |
2020-06-24 |
Bristol Myers Squibb Co |
Combinación de anticuerpos anti-CTLA4 con gemcitabina para el tratamiento sinérgico de enfermedades proliferativas
|
CA2769595A1
(en)
|
2009-08-14 |
2011-02-17 |
Roche Glycart Ag |
Combination therapy of an afucosylated cd20 antibody with fludarabine and/or mitoxantrone
|
TWI409079B
(zh)
|
2009-08-14 |
2013-09-21 |
Roche Glycart Ag |
非典型岩藻醣化cd20抗體與苯達莫斯汀(bendamustine)之組合療法
|
KR20120104517A
(ko)
|
2009-09-03 |
2012-09-21 |
제넨테크, 인크. |
류마티스 관절염의 치료, 진단 및 모니터링 방법
|
AR078161A1
(es)
|
2009-09-11 |
2011-10-19 |
Hoffmann La Roche |
Formulaciones farmaceuticas muy concentradas de un anticuerpo anti cd20. uso de la formulacion. metodo de tratamiento.
|
US20110070227A1
(en)
*
|
2009-09-18 |
2011-03-24 |
Anna-Marie Novotney-Barry |
Treatment of Autoimmune and Inflammatory Diseases
|
EP2322555A1
(en)
|
2009-11-11 |
2011-05-18 |
Ganymed Pharmaceuticals AG |
Antibodies specific for claudin 6 (CLDN6)
|
EP3305813B1
(en)
|
2009-11-11 |
2020-01-15 |
Ganymed Pharmaceuticals GmbH |
Antibodies specific for claudin 6 (cldn6)
|
US11377485B2
(en)
|
2009-12-02 |
2022-07-05 |
Academia Sinica |
Methods for modifying human antibodies by glycan engineering
|
US10087236B2
(en)
|
2009-12-02 |
2018-10-02 |
Academia Sinica |
Methods for modifying human antibodies by glycan engineering
|
TW201129383A
(en)
|
2010-02-10 |
2011-09-01 |
Immunogen Inc |
CD20 antibodies and uses thereof
|
US9173961B2
(en)
*
|
2010-02-10 |
2015-11-03 |
Immunogen, Inc. |
CD20 antibodies and uses thereof
|
CN103124564B
(zh)
|
2010-03-22 |
2016-11-09 |
弗·哈夫曼-拉罗切有限公司 |
对于稳定含有蛋白质的制剂有用的组合物和方法
|
EP2371864A1
(en)
|
2010-03-23 |
2011-10-05 |
Ganymed Pharmaceuticals AG |
Monoclonal antibodies for treatment of cancer
|
WO2011130332A1
(en)
|
2010-04-12 |
2011-10-20 |
Academia Sinica |
Glycan arrays for high throughput screening of viruses
|
MX353144B
(es)
|
2010-04-20 |
2017-12-20 |
Genmab As |
Proteinas que contienen fc de anticuerpos heterodimericos y metodos para produccion de las mismas.
|
WO2011133886A2
(en)
†
|
2010-04-23 |
2011-10-27 |
Genentech, Inc. |
Production of heteromultimeric proteins
|
CN102844049B
(zh)
|
2010-04-27 |
2016-06-01 |
罗切格利卡特公司 |
无岩藻糖基化CD20抗体与mTOR抑制剂的联合疗法
|
MX2012012743A
(es)
|
2010-05-03 |
2012-11-23 |
Genentech Inc |
Composiciones y metodos utiles para reducir la viscosidad de formulaciones que contienen proteina.
|
EP2568976B1
(en)
|
2010-05-10 |
2015-09-30 |
Academia Sinica |
Zanamivir phosphonate congeners with anti-influenza activity and determining oseltamivir susceptibility of influenza viruses
|
EP2571577A1
(en)
|
2010-05-17 |
2013-03-27 |
Bristol-Myers Squibb Company |
Improved immunotherapeutic dosing regimens and combinations thereof
|
EP2576621B1
(en)
|
2010-05-27 |
2019-04-10 |
Genmab A/S |
Monoclonal antibodies against her2
|
DK2580243T3
(da)
|
2010-06-09 |
2020-01-13 |
Genmab As |
Antibodies against human cd38
|
BR112012033002B1
(pt)
|
2010-06-24 |
2021-10-13 |
Genentech, Inc |
Composição aquosa de matéria, método de inibição de agregação induzida por agitação e método de prevenção de oxidação
|
EP2404936A1
(en)
|
2010-07-06 |
2012-01-11 |
Ganymed Pharmaceuticals AG |
Cancer therapy using CLDN6 target-directed antibodies in vivo
|
KR20130045914A
(ko)
|
2010-08-03 |
2013-05-06 |
에프. 호프만-라 로슈 아게 |
만성 림프구성 백혈병(cll) 생체지표
|
EP3578205A1
(en)
|
2010-08-06 |
2019-12-11 |
ModernaTX, Inc. |
A pharmaceutical formulation comprising engineered nucleic acids and medical use thereof
|
AR082693A1
(es)
|
2010-08-17 |
2012-12-26 |
Roche Glycart Ag |
Terapia de combinacion de un anticuerpo anti-cd20 afucosilado con un anticuerpo anti-vegf
|
AU2011308496A1
(en)
|
2010-10-01 |
2013-05-02 |
Moderna Therapeutics, Inc. |
Engineered nucleic acids and methods of use thereof
|
CN103476793A
(zh)
|
2010-11-08 |
2013-12-25 |
基因技术公司 |
皮下施用的抗-il-6受体抗体
|
TWI807362B
(zh)
|
2010-11-30 |
2023-07-01 |
日商中外製藥股份有限公司 |
細胞傷害誘導治療劑
|
JP6157045B2
(ja)
*
|
2010-12-06 |
2017-07-05 |
公益財団法人がん研究会 |
Cd20認識モノクローナル抗体、ハイブリドーマ、cd20の検出方法および判定方法
|
CA2819436A1
(en)
|
2010-12-16 |
2012-06-21 |
Roche Glycart Ag |
Combination therapy of an afucosylated cd20 antibody with a mdm2 inhibitor
|
US20130315901A1
(en)
*
|
2011-01-10 |
2013-11-28 |
Glaxo Group Limited |
Novel uses
|
KR20140022815A
(ko)
|
2011-02-28 |
2014-02-25 |
제넨테크, 인크. |
B-세포 길항제에 대한 반응을 예측하기 위한 생물학적 마커 및 방법
|
JP2014511687A
(ja)
|
2011-03-31 |
2014-05-19 |
モデルナ セラピューティクス インコーポレイテッド |
工学操作された核酸の送達および製剤
|
US20140170149A1
(en)
|
2011-04-20 |
2014-06-19 |
Genmab A/S |
Bispecific antibodies against her2 and cd3
|
JP6177231B2
(ja)
|
2011-04-20 |
2017-08-09 |
ゲンマブ エー/エス |
Her2に対する二重特異性抗体
|
UA127584C2
(uk)
|
2011-05-13 |
2023-10-25 |
Астеллас Фарма Інк. |
Антитіла для лікування ракових захворювань, при яких експресується клаудин 6
|
BR122016016837A2
(pt)
|
2011-05-21 |
2019-08-27 |
Macrogenics Inc |
moléculas de ligação a cd3; anticorpos de ligação a cd3; composições farmacêuticas; e usos da molécula de ligação a cd3
|
EP2537933A1
(en)
|
2011-06-24 |
2012-12-26 |
Institut National de la Santé et de la Recherche Médicale (INSERM) |
An IL-15 and IL-15Ralpha sushi domain based immunocytokines
|
AU2012280267B2
(en)
|
2011-07-06 |
2016-04-21 |
Morphosys Ag |
Therapeutic combinations of anti-cd20 and anti-gm-csf antibodies and uses thereof
|
WO2013004841A1
(en)
|
2011-07-06 |
2013-01-10 |
Genmab A/S |
Modulation of complement-dependent cytotoxicity through modifications of the c-terminus of antibody heavy chains
|
UA117901C2
(uk)
|
2011-07-06 |
2018-10-25 |
Ґенмаб Б.В. |
Спосіб посилення ефекторної функції вихідного поліпептиду, його варіанти та їх застосування
|
CN102875678B
(zh)
*
|
2011-07-13 |
2014-08-06 |
无锡天演生物技术有限公司 |
全人源抗人cd20单抗分子及其应用
|
US9464124B2
(en)
|
2011-09-12 |
2016-10-11 |
Moderna Therapeutics, Inc. |
Engineered nucleic acids and methods of use thereof
|
CA2846322A1
(en)
*
|
2011-09-19 |
2013-03-28 |
Kymab Limited |
Manipulation of immunoglobulin gene diversity and multi-antibody therapeutics
|
PT3682905T
(pt)
|
2011-10-03 |
2022-04-07 |
Modernatx Inc |
Nucleósidos, nucleótidos e ácidos nucleicos modificados e respetivas utilizações
|
JP6316195B2
(ja)
|
2011-10-26 |
2018-04-25 |
エランコ ティーアゲズンタイト アーゲー |
モノクローナル抗体および使用の方法
|
RS59166B1
(sr)
|
2011-10-27 |
2019-10-31 |
Genmab As |
Proizvodnja heterodimernih proteina
|
KR102168733B1
(ko)
|
2011-10-31 |
2020-10-23 |
추가이 세이야쿠 가부시키가이샤 |
중쇄와 경쇄의 회합이 제어된 항원 결합 분자
|
US20130302274A1
(en)
|
2011-11-25 |
2013-11-14 |
Roche Glycart Ag |
Combination therapy
|
HRP20220717T1
(hr)
|
2011-12-16 |
2022-07-22 |
Modernatx, Inc. |
Modificirani pripravci mrna
|
ES2697676T3
(es)
|
2011-12-22 |
2019-01-25 |
Hoffmann La Roche |
Cromatografía de membrana de intercambio iónico
|
TW201334789A
(zh)
|
2012-01-31 |
2013-09-01 |
Genentech Inc |
抗ige抗體及其使用方法
|
CN102585000B
(zh)
*
|
2012-02-22 |
2013-05-29 |
尉军 |
一种肿瘤标志物cd25自身抗体及应用
|
US20150110779A1
(en)
|
2012-03-15 |
2015-04-23 |
Bristol-Myers Squibb Company |
Methods for predicting gastrointestinal immune-related adverse events (gi-irae) in patients treated with modulation of the co-stimulatory pathway
|
US9283287B2
(en)
|
2012-04-02 |
2016-03-15 |
Moderna Therapeutics, Inc. |
Modified polynucleotides for the production of nuclear proteins
|
EP2834358A4
(en)
|
2012-04-02 |
2016-03-09 |
Moderna Therapeutics Inc |
MODIFIED POLYNUCLEOTIDES FOR THE PRODUCTION OF NUCLEAR PROTEINS
|
US9572897B2
(en)
|
2012-04-02 |
2017-02-21 |
Modernatx, Inc. |
Modified polynucleotides for the production of cytoplasmic and cytoskeletal proteins
|
US9254311B2
(en)
|
2012-04-02 |
2016-02-09 |
Moderna Therapeutics, Inc. |
Modified polynucleotides for the production of proteins
|
US10130714B2
(en)
|
2012-04-14 |
2018-11-20 |
Academia Sinica |
Enhanced anti-influenza agents conjugated with anti-inflammatory activity
|
EP2662386B1
(en)
|
2012-05-07 |
2019-03-06 |
Astellas Pharma Inc. |
Antibodies that bind to PLAC1 and block interaction between PLAC1 and FGF7
|
WO2013167153A1
(en)
|
2012-05-09 |
2013-11-14 |
Ganymed Pharmaceuticals Ag |
Antibodies useful in cancer diagnosis
|
WO2013169971A1
(en)
|
2012-05-10 |
2013-11-14 |
Bristol-Myers Squibb Company |
Anti-tumor antibodies as predictive or prognostic biomarkers of efficacy and survival in ipilimumab-treated patients
|
ES2682761T3
(es)
|
2012-05-18 |
2018-09-21 |
Genentech, Inc. |
Formulaciones de anticuerpos monoclonales de alta concentración
|
EP3725810B1
(en)
|
2012-05-23 |
2022-07-06 |
Astellas Pharma Inc. |
Combination therapy involving antibodies against claudin 18.2 for treatment of cancer
|
WO2013174404A1
(en)
|
2012-05-23 |
2013-11-28 |
Ganymed Pharmaceuticals Ag |
Combination therapy involving antibodies against claudin 18.2 for treatment of cancer
|
DK3254695T3
(da)
|
2012-05-23 |
2020-11-30 |
Astellas Pharma Inc |
Kombinationsterapi, der involverer antistoffer mod claudin 18.2 til behandling af cancer
|
WO2013174403A1
(en)
|
2012-05-23 |
2013-11-28 |
Ganymed Pharmaceuticals Ag |
Combination therapy involving antibodies against claudin 18.2 for treatment of cancer
|
PT2869845T
(pt)
*
|
2012-07-06 |
2019-12-09 |
Genmab Bv |
Proteína dimérica com mutações triplas
|
AU2013285355A1
(en)
|
2012-07-06 |
2015-01-29 |
Genmab B.V. |
Dimeric protein with triple mutations
|
EP3632462A1
(en)
|
2012-07-06 |
2020-04-08 |
Genmab B.V. |
Dimeric protein with triple mutations
|
CN103588882B
(zh)
*
|
2012-08-13 |
2015-10-28 |
中国抗体制药有限公司 |
针对人cd22抗体的抗独特型抗体及其应用
|
JP6302909B2
(ja)
|
2012-08-18 |
2018-03-28 |
アカデミア シニカAcademia Sinica |
シアリダーゼの同定および画像化のための細胞透過性プローブ
|
US9547009B2
(en)
|
2012-08-21 |
2017-01-17 |
Academia Sinica |
Benzocyclooctyne compounds and uses thereof
|
US8643360B1
(en)
*
|
2012-09-02 |
2014-02-04 |
George S. Cargill, III |
In-water voltage gradient detector
|
WO2014039855A1
(en)
|
2012-09-07 |
2014-03-13 |
Genentech, Inc. |
Combination therapy of a type ii anti-cd20 antibody with a selective bcl-2 inhibitor
|
JOP20200236A1
(ar)
|
2012-09-21 |
2017-06-16 |
Regeneron Pharma |
الأجسام المضادة لمضاد cd3 وجزيئات ربط الأنتيجين ثنائية التحديد التي تربط cd3 وcd20 واستخداماتها
|
JP6273205B2
(ja)
|
2012-10-05 |
2018-01-31 |
協和発酵キリン株式会社 |
ヘテロダイマータンパク質組成物
|
AU2013337926B2
(en)
*
|
2012-10-30 |
2017-12-21 |
Esperance Pharmaceuticals, Inc. |
Antibody/drug conjugates and methods of use
|
SG11201503593UA
(en)
|
2012-11-13 |
2015-06-29 |
Biontech Ag |
Agents for treatment of claudin expressing cancer diseases
|
BR122020024124B1
(pt)
|
2012-11-13 |
2024-01-30 |
Biontech Ag |
Agentes para tratamento de doenças cancerosas expressando claudina
|
WO2014075697A1
(en)
|
2012-11-13 |
2014-05-22 |
Biontech Ag |
Agents for treatment of claudin expressing cancer diseases
|
EP4074834A1
(en)
|
2012-11-26 |
2022-10-19 |
ModernaTX, Inc. |
Terminally modified rna
|
CN103173412B
(zh)
*
|
2012-12-07 |
2015-04-22 |
天津三箭生物技术有限公司 |
小鼠抗人cd20单克隆抗体及分泌该单克隆抗体的杂交瘤细胞株
|
CN105229026B
(zh)
|
2013-01-10 |
2021-07-30 |
根马布私人有限公司 |
人类IgG1 FC区变体及其用途
|
CN103145847B
(zh)
*
|
2013-02-05 |
2014-05-21 |
浙江大学 |
一种抗cd20抗体-海兔毒素偶联物及其制备方法和应用
|
WO2014127785A1
(en)
|
2013-02-20 |
2014-08-28 |
Ganymed Pharmaceuticals Ag |
Combination therapy involving antibodies against claudin 18.2 for treatment of cancer
|
RS63738B1
(sr)
|
2013-02-20 |
2022-12-30 |
Astellas Pharma Inc |
Kombinovana terapija koja uključuje antitela protiv klaudina 18.2 za lečenje kancera
|
RU2694055C2
(ru)
|
2013-03-13 |
2019-07-09 |
Дженентек, Инк. |
Составы антител
|
US8980864B2
(en)
|
2013-03-15 |
2015-03-17 |
Moderna Therapeutics, Inc. |
Compositions and methods of altering cholesterol levels
|
FR3003171B1
(fr)
*
|
2013-03-15 |
2015-04-10 |
Lab Francais Du Fractionnement |
Nouveaux medicaments comprenant une composition d'anticorps enrichie en isoforme de charge majoritaire
|
WO2014146672A1
(en)
|
2013-03-18 |
2014-09-25 |
Ganymed Pharmaceuticals Ag |
Therapy involving antibodies against claudin 18.2 for treatment of cancer
|
EP3670537A1
(en)
|
2013-03-18 |
2020-06-24 |
Astellas Pharma Inc. |
Therapy involving antibodies against claudin 18.2 for treatment of cancer
|
RU2015147696A
(ru)
|
2013-04-09 |
2017-05-12 |
Бостон Байомедикал, Инк. |
Способы лечения злокачественной опухоли
|
CN105324124A
(zh)
|
2013-04-19 |
2016-02-10 |
赛腾制药 |
降低的血管渗漏综合征的细胞因子衍生治疗
|
CN103254317B
(zh)
*
|
2013-05-08 |
2014-08-13 |
浙江大学 |
一种抗cd20单克隆抗体-海兔毒素偶联物及其制备方法和应用
|
WO2014210397A1
(en)
|
2013-06-26 |
2014-12-31 |
Academia Sinica |
Rm2 antigens and use thereof
|
US9981030B2
(en)
|
2013-06-27 |
2018-05-29 |
Academia Sinica |
Glycan conjugates and use thereof
|
IL311371B2
(en)
*
|
2013-07-05 |
2024-09-01 |
Genmab As |
CD3 antibodies of human origin or chimeras
|
WO2015014376A1
(en)
|
2013-07-31 |
2015-02-05 |
Biontech Ag |
Diagnosis and therapy of cancer involving cancer stem cells
|
EP3747465A1
(en)
|
2013-07-31 |
2020-12-09 |
BioNTech AG |
Diagnosis and therapy of cancer involving cancer stem cells
|
DK3030575T3
(da)
|
2013-08-08 |
2018-10-22 |
Cytune Pharma |
Il-15- og il-15r-alfa-sushi-domænebaserede modulokiner
|
RS59756B1
(sr)
|
2013-08-08 |
2020-02-28 |
Cytune Pharma |
Kombinovana farmaceutska kompozicija
|
CN103467605B
(zh)
*
|
2013-09-05 |
2015-02-04 |
武汉友芝友生物制药有限公司 |
一种cd3抗原及其制备方法和用途
|
JP6486368B2
(ja)
|
2013-09-06 |
2019-03-20 |
アカデミア シニカAcademia Sinica |
改変されたグリコシル基を含む糖脂質を用いたヒトiNKT細胞の活性化
|
EP3052106A4
(en)
|
2013-09-30 |
2017-07-19 |
ModernaTX, Inc. |
Polynucleotides encoding immune modulating polypeptides
|
EP3052521A1
(en)
|
2013-10-03 |
2016-08-10 |
Moderna Therapeutics, Inc. |
Polynucleotides encoding low density lipoprotein receptor
|
MX2016005925A
(es)
|
2013-11-05 |
2016-11-28 |
Cognate Bioservices Inc |
Combinaciones de inhibidores de punto de regulacion y terapeuticos para tratar el cancer.
|
WO2015069703A1
(en)
|
2013-11-06 |
2015-05-14 |
Bristol-Myers Squibb Company |
Immunotherapeutic dosing regimens and combinations thereof
|
AU2014345712B2
(en)
*
|
2013-11-07 |
2019-10-17 |
F. Hoffmann-La Roche Ag |
Combination therapy of an anti CD20 antibody with a BTK inhibitor
|
ES2839087T3
(es)
|
2013-11-12 |
2021-07-05 |
Ogd2 Pharma |
Anticuerpo derivado de IGG1 humana con actividad pro-apoptótica
|
KR20160089532A
(ko)
|
2013-12-17 |
2016-07-27 |
제넨테크, 인크. |
Pd-1 축 결합 길항제 및 항-cd20 항체를 사용하여 암을 치료하는 방법
|
CA2937123A1
(en)
|
2014-01-16 |
2015-07-23 |
Academia Sinica |
Compositions and methods for treatment and detection of cancers
|
US10150818B2
(en)
|
2014-01-16 |
2018-12-11 |
Academia Sinica |
Compositions and methods for treatment and detection of cancers
|
EP2910645A1
(en)
|
2014-02-25 |
2015-08-26 |
STRATIFYER Molecular Pathology GmbH |
Methods and compositions for prediction of therapeutic efficacy of cancer treatments and cancer prognosis upon antibody treatment
|
EP2915569A1
(en)
|
2014-03-03 |
2015-09-09 |
Cytune Pharma |
IL-15/IL-15Ralpha based conjugates purification method
|
TWI754319B
(zh)
|
2014-03-19 |
2022-02-01 |
美商再生元醫藥公司 |
用於腫瘤治療之方法及抗體組成物
|
CN103880958B
(zh)
*
|
2014-03-27 |
2016-01-20 |
安徽大学 |
抗cd20抗原的抗体l4h6及其应用
|
EP3129767B1
(en)
|
2014-03-27 |
2021-09-01 |
Academia Sinica |
Reactive labelling compounds and uses thereof
|
CN103880957B
(zh)
*
|
2014-03-27 |
2016-01-20 |
安徽大学 |
抗cd20抗原的抗体l1h1及其应用
|
WO2015156268A1
(ja)
|
2014-04-07 |
2015-10-15 |
中外製薬株式会社 |
免疫活性化抗原結合分子
|
US20170049887A1
(en)
|
2014-04-25 |
2017-02-23 |
University Of Florida Research Foundation, Inc. |
Methods of permitting a subject to receive multiple doses of recombinant adeno-associated virus
|
MX2016014409A
(es)
|
2014-05-06 |
2017-01-20 |
Genentech Inc |
Produccion de proteinas heteromultimericas usando celulas de mamifero.
|
JP6894702B2
(ja)
|
2014-05-13 |
2021-06-30 |
中外製薬株式会社 |
免疫抑制機能を有する細胞に対するt細胞リダイレクト抗原結合分子
|
EP3149045B1
(en)
|
2014-05-27 |
2023-01-18 |
Academia Sinica |
Compositions and methods relating to universal glycoforms for enhanced antibody efficacy
|
WO2015184004A1
(en)
|
2014-05-27 |
2015-12-03 |
Academia Sinica |
Anti-cd20 glycoantibodies and uses thereof
|
WO2015184002A1
(en)
|
2014-05-27 |
2015-12-03 |
Academia Sinica |
Anti-her2 glycoantibodies and uses thereof
|
US10118969B2
(en)
|
2014-05-27 |
2018-11-06 |
Academia Sinica |
Compositions and methods relating to universal glycoforms for enhanced antibody efficacy
|
CA2950433A1
(en)
|
2014-05-28 |
2015-12-03 |
Academia Sinica |
Anti-tnf-alpha glycoantibodies and uses thereof
|
EP3191500A4
(en)
|
2014-09-08 |
2018-04-11 |
Academia Sinica |
HUMAN iNKT CELL ACTIVATION USING GLYCOLIPIDS
|
JP7072384B2
(ja)
|
2014-09-15 |
2022-05-20 |
ジェネンテック, インコーポレイテッド |
抗体製剤
|
PT3262071T
(pt)
|
2014-09-23 |
2020-06-16 |
H Hoffnabb La Roche Ag |
Métodos de utilização de imunoconjugados anti-cd79b
|
MA40764A
(fr)
|
2014-09-26 |
2017-08-01 |
Chugai Pharmaceutical Co Ltd |
Agent thérapeutique induisant une cytotoxicité
|
CN115040532A
(zh)
|
2014-10-10 |
2022-09-13 |
伊黛拉制药有限公司 |
使用tlr9激动剂与检查点抑制剂对癌症的治疗
|
EP3221359B1
(en)
|
2014-11-17 |
2020-05-27 |
Regeneron Pharmaceuticals, Inc. |
Methods for tumor treatment using cd3xcd20 bispecific antibody
|
MX2017007097A
(es)
|
2014-12-04 |
2017-09-05 |
Bristol Myers Squibb Co |
Combinacion de anticuerpos anti-cs1 y anti-muerte programada 1 (pd1) para tratar cancer (mieloma).
|
EP3240805A4
(en)
|
2014-12-15 |
2018-05-09 |
The Regents of the University of California |
Bispecific or-gate chimeric antigen receptor responsive to cd19 and cd20
|
US10865253B2
(en)
|
2014-12-19 |
2020-12-15 |
Genmab A/S |
Rodent bispecific heterodimeric proteins
|
CA2973159A1
(en)
*
|
2015-01-08 |
2016-07-14 |
Genmab A/S |
Bispecific antibodies against cd3 and cd20
|
US10495645B2
(en)
|
2015-01-16 |
2019-12-03 |
Academia Sinica |
Cancer markers and methods of use thereof
|
US9975965B2
(en)
|
2015-01-16 |
2018-05-22 |
Academia Sinica |
Compositions and methods for treatment and detection of cancers
|
CA2972072A1
(en)
|
2015-01-24 |
2016-07-28 |
Academia Sinica |
Novel glycan conjugates and methods of use thereof
|
EP3250588A1
(en)
|
2015-01-29 |
2017-12-06 |
Board of Trustees of Michigan State University |
Cryptic polypeptides and uses thereof
|
SG11201707144VA
(en)
*
|
2015-03-04 |
2017-09-28 |
Igm Biosciences Inc |
Cd20 binding molecules and uses thereof
|
US20180133327A1
(en)
|
2015-03-16 |
2018-05-17 |
Amal Therapeutics Sa |
Cell Penetrating Peptides and Complexes Comprising the Same
|
EP3273974A4
(en)
|
2015-03-26 |
2018-11-07 |
Women and Infants Hospital of Rhode Island Inc. |
Therapy for malignant disease
|
WO2016165762A1
(en)
|
2015-04-15 |
2016-10-20 |
Ganymed Pharmaceuticals Ag |
Drug conjugates comprising antibodies against claudin 18.2
|
WO2016165765A1
(en)
|
2015-04-15 |
2016-10-20 |
Ganymed Pharmaceuticals Ag |
Methods and compositions for prediction of therapeutic efficacy of cancer treatments and cancer prognosis
|
EP3289869B1
(en)
*
|
2015-04-30 |
2020-10-14 |
Institute Of Immunology Co., Ltd. |
Transgenic non-human animal expressing human-specific molecules and human fc gamma receptor family
|
EP3294334B1
(en)
|
2015-05-11 |
2020-07-08 |
The Johns Hopkins University |
Autoimmune antibodies for use in inhibiting cancer cell growth
|
EP3936524A3
(en)
|
2015-05-11 |
2022-06-15 |
F. Hoffmann-La Roche AG |
Compositions and methods of treating lupus nephritis
|
KR101997241B1
(ko)
|
2015-05-21 |
2019-07-09 |
하푼 테라퓨틱스, 인크. |
삼중특이성 결합 단백질 및 사용 방법
|
CA3176224A1
(en)
|
2015-05-22 |
2016-12-01 |
Translational Drug Development Llc |
Benzamide and active compound compositions and methods of use
|
KR20180015195A
(ko)
|
2015-06-03 |
2018-02-12 |
보스톤 바이오메디칼, 인크. |
암의 치료에 사용하기 위한 암 줄기능 저해제 및 면역치료제를 포함하는 조성물
|
EP3108897A1
(en)
|
2015-06-24 |
2016-12-28 |
F. Hoffmann-La Roche AG |
Antibodies against human csf-1r for use in inducing lymphocytosis in lymphomas or leukemias
|
BR112017024610A2
(pt)
|
2015-06-24 |
2018-07-31 |
F. Hoffmann-La Roche Ag |
anticorpos para receptor antitransferrina com afinidade especificada
|
JOP20200312A1
(ar)
|
2015-06-26 |
2017-06-16 |
Novartis Ag |
الأجسام المضادة للعامل xi وطرق الاستخدام
|
MX2017016645A
(es)
|
2015-06-29 |
2018-11-09 |
Genentech Inc |
Anticuerpo anti-cd20 de tipo ii para su uso en el trasplante de órganos.
|
SI3313528T1
(sl)
|
2015-06-29 |
2021-11-30 |
Bristol-Myers Squibb Company |
Imunoterapevtski režim odmerjanja, ki vsebujejo pomalidomid in protitelo anti-CS1 za zdravljenje raka
|
US20180201693A1
(en)
|
2015-07-09 |
2018-07-19 |
Genmab A/S |
Bispecific and multispecific antibodies and method for isolation of such
|
MX2017016844A
(es)
|
2015-07-16 |
2018-08-15 |
Biokine Therapeutics Ltd |
Composiciones y procedimientos para tratar cancer.
|
US10660954B2
(en)
|
2015-07-31 |
2020-05-26 |
University Of Florida Research Foundation, Incorporated |
Hematopoietic stem cells in combinatorial therapy with immune checkpoint inhibitors against cancer
|
WO2017025871A1
(en)
|
2015-08-07 |
2017-02-16 |
Glaxosmithkline Intellectual Property Development Limited |
Combination therapy comprising anti ctla-4 antibodies
|
US11098079B2
(en)
|
2015-08-13 |
2021-08-24 |
Amgen Inc. |
Charged depth filtration of antigen-binding proteins
|
JP7002446B2
(ja)
|
2015-09-21 |
2022-03-04 |
アプティーボ リサーチ アンド デベロップメント エルエルシー |
Cd3結合ポリペプチド
|
AR106188A1
(es)
|
2015-10-01 |
2017-12-20 |
Hoffmann La Roche |
Anticuerpos anti-cd19 humano humanizados y métodos de utilización
|
AR106189A1
(es)
|
2015-10-02 |
2017-12-20 |
Hoffmann La Roche |
ANTICUERPOS BIESPECÍFICOS CONTRA EL A-b HUMANO Y EL RECEPTOR DE TRANSFERRINA HUMANO Y MÉTODOS DE USO
|
IL258317B1
(en)
|
2015-10-02 |
2024-08-01 |
Hoffmann La Roche |
Human anti–CD20/human transferrin receptor bispecific antibodies and methods of use
|
KR20180083859A
(ko)
*
|
2015-10-13 |
2018-07-23 |
유레카 쎄라퓨틱스, 인코포레이티드 |
인간 cd19에 특이적인 항체 작용제 및 그의 용도
|
WO2017086419A1
(ja)
|
2015-11-18 |
2017-05-26 |
中外製薬株式会社 |
液性免疫応答の増強方法
|
EP3378487B1
(en)
|
2015-11-18 |
2022-03-16 |
Chugai Seiyaku Kabushiki Kaisha |
Combination therapy using t cell redirection antigen binding molecule against cell having immunosuppressing function
|
PL3387015T3
(pl)
|
2015-12-09 |
2022-02-14 |
F. Hoffmann-La Roche Ag |
Przeciwciało anty-CD20 typu II do ograniczania tworzenia przeciwciał przeciwlekowych
|
EP3178848A1
(en)
|
2015-12-09 |
2017-06-14 |
F. Hoffmann-La Roche AG |
Type ii anti-cd20 antibody for reducing formation of anti-drug antibodies
|
CN105348388B
(zh)
*
|
2015-12-11 |
2018-10-19 |
安徽大学 |
抗cd20抗原的抗体l3h3及其应用
|
JP7219005B2
(ja)
|
2015-12-28 |
2023-02-07 |
中外製薬株式会社 |
Fc領域含有ポリペプチドの精製を効率化するための方法
|
US10525137B2
(en)
|
2015-12-30 |
2020-01-07 |
Genentech, Inc. |
Formulations with reduced degradation of polysorbate
|
JP2019515874A
(ja)
|
2016-03-01 |
2019-06-13 |
エフ・ホフマン−ラ・ロシュ・アクチェンゲゼルシャフト |
改変された細胞死誘導を有するオビヌツズマブ変異体
|
WO2017149018A1
(en)
|
2016-03-02 |
2017-09-08 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods and kits for predicting the risk of relapse in patients suffering from idiopathic nephrotic syndrome
|
US10336784B2
(en)
|
2016-03-08 |
2019-07-02 |
Academia Sinica |
Methods for modular synthesis of N-glycans and arrays thereof
|
RU2746754C2
(ru)
|
2016-03-14 |
2021-04-20 |
Чугаи Сейяку Кабусики Кайся |
Индуцирующее повреждение клеток терапевтическое лекарственное средство, предназначенное для противораковой терапии
|
WO2017160599A1
(en)
|
2016-03-14 |
2017-09-21 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Use of cd300b antagonists to treat sepsis and septic shock
|
KR102413037B1
(ko)
|
2016-03-15 |
2022-06-23 |
메르사나 테라퓨틱스, 인코포레이티드 |
Napi2b 표적화된 항체-약물 접합체 및 이의 사용 방법
|
HRP20240510T1
(hr)
|
2016-03-16 |
2024-07-05 |
Amal Therapeutics Sa |
Kombinacija modulatora imunosne kontrolne točke i kompleksa koji sadrži peptid koji prodire u stanicu, teretni i tlr peptidni agonist za uporabu u medicini
|
JP2019514870A
(ja)
|
2016-04-22 |
2019-06-06 |
アンスティチュ ナショナル ドゥ ラ サンテ エ ドゥ ラ ルシェルシュ メディカル |
B細胞悪性腫瘍の処置のための方法及びワクチン組成物
|
US20190298824A1
(en)
|
2016-05-04 |
2019-10-03 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Serv |
Albumin-binding immunomodulatory compositions and methods of use thereof
|
US11623958B2
(en)
|
2016-05-20 |
2023-04-11 |
Harpoon Therapeutics, Inc. |
Single chain variable fragment CD3 binding proteins
|
TW201802121A
(zh)
|
2016-05-25 |
2018-01-16 |
諾華公司 |
抗因子XI/XIa抗體之逆轉結合劑及其用途
|
US11052148B2
(en)
|
2016-05-30 |
2021-07-06 |
Geo Vax, Inc. |
Compositions and methods for generating an immune response to hepatitis B virus
|
EP3252078A1
(en)
|
2016-06-02 |
2017-12-06 |
F. Hoffmann-La Roche AG |
Type ii anti-cd20 antibody and anti-cd20/cd3 bispecific antibody for treatment of cancer
|
CN110603266A
(zh)
|
2016-06-02 |
2019-12-20 |
豪夫迈·罗氏有限公司 |
用于治疗癌症的ii型抗cd20抗体和抗cd20/cd3双特异性抗体
|
HRP20240815T1
(hr)
|
2016-06-14 |
2024-09-27 |
Regeneron Pharmaceuticals, Inc. |
Anti-c5 antitijela i njihove upotrebe
|
EP3472614A1
(en)
*
|
2016-06-16 |
2019-04-24 |
F. Hoffmann-La Roche AG |
Assay and method for determining cdc eliciting antibodies
|
SG11201811600PA
(en)
|
2016-06-30 |
2019-01-30 |
Oncorus Inc |
Pseudotyped oncolytic viral delivery of therapeutic polypeptides
|
CN106267406B
(zh)
*
|
2016-07-01 |
2019-02-01 |
翁炳焕 |
艾滋病血液净化器
|
EP3494140A1
(en)
|
2016-08-04 |
2019-06-12 |
GlaxoSmithKline Intellectual Property Development Ltd |
Anti-icos and anti-pd-1 antibody combination therapy
|
WO2018039274A1
(en)
|
2016-08-22 |
2018-03-01 |
CHO Pharma Inc. |
Antibodies, binding fragments, and methods of use
|
EP3507303A1
(en)
*
|
2016-09-01 |
2019-07-10 |
UMC Utrecht Holding B.V. |
Cd20 antibodies
|
KR20230131498A
(ko)
|
2016-09-21 |
2023-09-13 |
아말 테라퓨틱스 에스에이 |
암 치료를 위한, 세포 투과 펩타이드, 멀티 에피토프 및 tlr 펩타이드 작용제를 포함하는 융합체
|
WO2018054484A1
(en)
|
2016-09-23 |
2018-03-29 |
Biontech Ag |
Bispecific trivalent antibodies binding to claudin 6 or claudin18.2 and cd3 for treatment of claudin expressing cancer diseases
|
US20190276549A1
(en)
|
2016-11-01 |
2019-09-12 |
Genmab B.V. |
Polypeptide variants and uses thereof
|
US10780080B2
(en)
|
2016-11-23 |
2020-09-22 |
Translational Drug Development, Llc |
Benzamide and active compound compositions and methods of use
|
US11135307B2
(en)
|
2016-11-23 |
2021-10-05 |
Mersana Therapeutics, Inc. |
Peptide-containing linkers for antibody-drug conjugates
|
WO2018102427A1
(en)
|
2016-11-29 |
2018-06-07 |
Boston Biomedical, Inc. |
Naphthofuran derivatives, preparation, and methods of use thereof
|
WO2018099539A1
(en)
|
2016-11-29 |
2018-06-07 |
Horst Lindhofer |
Combination of t-cell redirecting multifunctional antibodies with immune checkpoint modulators and uses thereof
|
EP3548068A1
(en)
|
2016-12-01 |
2019-10-09 |
GlaxoSmithKline Intellectual Property Development Limited |
Combination therapy
|
BR112019011370A2
(pt)
|
2016-12-01 |
2019-10-15 |
Glaxosmithkline Ip Dev Ltd |
terapia de combinação
|
WO2018100096A1
(en)
|
2016-12-01 |
2018-06-07 |
Inserm (Institut National De La Sante Et De La Recherche Medicale) |
Use of anti-uchl1 igg plasma concentration for diagnosing idiopathic steroid sensitive nephrotic syndrome
|
CA3045296A1
(en)
|
2016-12-07 |
2018-06-14 |
Progenity, Inc. |
Gastrointestinal tract detection methods, devices and systems
|
WO2018114754A1
(en)
|
2016-12-19 |
2018-06-28 |
F. Hoffmann-La Roche Ag |
Combination therapy with targeted 4-1bb (cd137) agonists
|
CA3039446A1
(en)
|
2016-12-20 |
2018-06-28 |
F. Hoffmann-La Roche Ag |
Combination therapy of anti-cd20/anti-cd3 bispecific antibodies and 4-1bb (cd137) agonists
|
US11168147B2
(en)
|
2016-12-23 |
2021-11-09 |
Novartis Ag |
Factor XI antibodies and methods of use
|
WO2018148381A1
(en)
|
2017-02-07 |
2018-08-16 |
Nantcell, Inc. |
Maximizing t-cell memory and compositions and methods therefor
|
CN108395482B
(zh)
|
2017-02-08 |
2021-02-05 |
西比曼生物科技(香港)有限公司 |
一种靶向cd20抗原嵌合抗原受体的构建及其工程化t细胞的活性鉴定
|
MX2019009346A
(es)
|
2017-02-10 |
2019-10-02 |
Genmab Bv |
Variantes de polipeptidos y usos de los mismos.
|
WO2018160538A1
(en)
|
2017-02-28 |
2018-09-07 |
Mersana Therapeutics, Inc. |
Combination therapies of her2-targeted antibody-drug conjugates
|
EP3596469A1
(en)
|
2017-03-12 |
2020-01-22 |
Yeda Research and Development Co., Ltd. |
Methods of diagnosing and prognosing cancer
|
WO2018167780A1
(en)
|
2017-03-12 |
2018-09-20 |
Yeda Research And Development Co. Ltd. |
Methods of prognosing and treating cancer
|
EP3600416B1
(en)
|
2017-03-30 |
2023-06-07 |
Biora Therapeutics, Inc. |
Treatment of a disease of the gastrointestinal tract with an immune modulatory agent released using an ingestible device
|
CN110914301B
(zh)
|
2017-03-31 |
2024-09-06 |
健玛保控股有限公司 |
双特异性抗cd37抗体,单克隆抗cd37抗体及其使用方法
|
CN113896792A
(zh)
|
2017-05-12 |
2022-01-07 |
哈普恩治疗公司 |
间皮素结合蛋白质
|
CA3062656A1
(en)
|
2017-05-17 |
2018-11-22 |
Boston Biomedical, Inc. |
Methods for treating cancer
|
CN110719799A
(zh)
|
2017-06-09 |
2020-01-21 |
俄勒冈州普罗维登斯健康与服务部 |
Cd39和cd103在鉴定用于癌症治疗的人肿瘤反应性t细胞中的应用
|
CN107446046A
(zh)
*
|
2017-07-05 |
2017-12-08 |
无锡傲锐东源生物科技有限公司 |
抗cd20蛋白单克隆抗体及其用途
|
JP2020528061A
(ja)
|
2017-07-26 |
2020-09-17 |
エフ・ホフマン−ラ・ロシュ・アクチェンゲゼルシャフト |
BET阻害剤、Bcl−2阻害剤及び抗CD20抗体を用いた併用療法
|
WO2019036855A1
(en)
|
2017-08-21 |
2019-02-28 |
Adagene Inc. |
ANTI-CD137 MOLECULES AND THEIR USE
|
WO2019048040A1
(en)
|
2017-09-06 |
2019-03-14 |
Ganymed Pharmaceuticals Gmbh |
ANTIBODIES USEFUL IN THE DIAGNOSIS OF CANCER
|
CR20200195A
(es)
|
2017-10-13 |
2020-08-14 |
Harpoon Therapeutics Inc |
Proteínas de unión a antigenos de maduraciòn de celulas b
|
WO2019077123A1
(en)
|
2017-10-20 |
2019-04-25 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
METHODS AND KITS FOR IDENTIFYING WHETHER A SUBJECT IS REACHED OR RISK OF BEING WITH AUTOIMMUNE MYOPATHY
|
WO2019104289A1
(en)
|
2017-11-27 |
2019-05-31 |
Mersana Therapeutics, Inc. |
Pyrrolobenzodiazepine antibody conjugates
|
AU2018382966A1
(en)
|
2017-12-14 |
2020-04-09 |
F. Hoffmann-La Roche Ag |
Use of a CEA CD3 bispecific antibody and a PD-1 axis binding antagonist in a dosage regime to treat cancer
|
TW201929908A
(zh)
|
2017-12-21 |
2019-08-01 |
美商梅爾莎納醫療公司 |
吡咯并苯并二氮呯抗體共軛物
|
EP3731850A4
(en)
|
2017-12-29 |
2021-12-01 |
Oncorus, Inc. |
ONCOLYTIC VIRUS DELIVERY OF THERAPEUTIC POLYPEPTIDES
|
EP3743440A1
(en)
|
2018-01-24 |
2020-12-02 |
Genmab B.V. |
Polypeptide variants and uses thereof
|
WO2019148445A1
(en)
|
2018-02-02 |
2019-08-08 |
Adagene Inc. |
Precision/context-dependent activatable antibodies, and methods of making and using the same
|
BR112020018585A8
(pt)
|
2018-03-12 |
2022-12-06 |
Inst Nat Sante Rech Med |
Uso de mimeticos de restrição calórica para potencializar a quimioimunoterapia para o tratamento de câncer
|
WO2019175071A1
(en)
|
2018-03-13 |
2019-09-19 |
F. Hoffmann-La Roche Ag |
Therapeutic combination of 4-1 bb agonists with anti-cd20 antibodies
|
TWI841551B
(zh)
|
2018-03-13 |
2024-05-11 |
瑞士商赫孚孟拉羅股份公司 |
使用靶向4-1bb (cd137)之促效劑的組合療法
|
CN112839958A
(zh)
|
2018-05-03 |
2021-05-25 |
根马布私人有限公司 |
抗体变体组合及其用途
|
EP3810109B1
(en)
|
2018-05-31 |
2024-08-07 |
Peloton Therapeutics, Inc. |
Compounds and compositions for inhibiting cd73
|
EP3807410A1
(en)
|
2018-06-15 |
2021-04-21 |
MiNA Therapeutics Limited |
Combination therapies comprising c/ebp alpha sarna
|
WO2019246312A1
(en)
|
2018-06-20 |
2019-12-26 |
Progenity, Inc. |
Treatment of a disease of the gastrointestinal tract with an immunomodulator
|
US20230009902A1
(en)
|
2018-06-20 |
2023-01-12 |
Progenity, Inc. |
Treatment of a disease or condition in a tissue orginating from the endoderm
|
WO2019243636A1
(en)
|
2018-06-22 |
2019-12-26 |
Genmab Holding B.V. |
Anti-cd37 antibodies and anti-cd20 antibodies, compositions and methods of use thereof
|
CN112513074A
(zh)
|
2018-06-22 |
2021-03-16 |
健玛保 |
生产两种或更多种不同抗体的受控混合物的方法
|
CN112384219A
(zh)
*
|
2018-07-09 |
2021-02-19 |
千禧制药公司 |
Sumo-激活酶抑制剂和抗cd20抗体的施用
|
GB201811408D0
(en)
|
2018-07-12 |
2018-08-29 |
F Star Beta Ltd |
CD137 Binding Molecules
|
WO2020033791A1
(en)
|
2018-08-09 |
2020-02-13 |
Verseau Therapeutics, Inc. |
Oligonucleotide compositions for targeting ccr2 and csf1r and uses thereof
|
MA53495A
(fr)
|
2018-08-31 |
2021-12-08 |
Regeneron Pharma |
Stratégie de dosage permettant d'atténuer le syndrome de libération de cytokines pour des anticorps bispécifiques cd3/c20
|
WO2020048942A1
(en)
|
2018-09-04 |
2020-03-12 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods and pharmaceutical compositions for enhancing cytotoxic t lymphocyte-dependent immune responses
|
CN112955172A
(zh)
|
2018-09-17 |
2021-06-11 |
美国卫生和人力服务部 |
靶向cd19和cd20的双顺反子嵌合抗原受体及其用途
|
US20220073638A1
(en)
|
2018-09-19 |
2022-03-10 |
INSERM (Institut National de la Santé et de la Recherche Médicale |
Methods and pharmaceutical composition for the treatment of cancers resistant to immune checkpoint therapy
|
KR20210086623A
(ko)
|
2018-09-25 |
2021-07-08 |
하푼 테라퓨틱스, 인크. |
Ddl3 결합 단백질 및 사용 방법
|
WO2020070053A1
(en)
|
2018-10-01 |
2020-04-09 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Use of inhibitors of stress granule formation for targeting the regulation of immune responses
|
US20240252635A1
(en)
|
2018-10-04 |
2024-08-01 |
Genmab Holding B.V. |
Pharmaceutical compositions comprising bispecific anti-cd37 antibodies
|
EP3868784A4
(en)
|
2018-10-15 |
2022-07-27 |
Industry-Academic Cooperation Foundation, Yonsei University |
ANTIBODIES WITH INCREASED PRODUCTIVITY AND METHODS FOR THEIR PRODUCTION
|
AU2019367218A1
(en)
*
|
2018-10-26 |
2021-06-03 |
TeneoFour, Inc. |
Heavy chain antibodies binding to CD38
|
EA202191175A1
(ru)
|
2018-10-29 |
2021-09-08 |
Мерсана Терапьютикс, Инк. |
Сконструированные с цистеином конъюгаты антитело-лекарственное средство, содержащие пептидсодержащие линкеры
|
WO2020106757A1
(en)
|
2018-11-19 |
2020-05-28 |
Progenity, Inc. |
Ingestible device for delivery of therapeutic agent to the gastrointestinal tract
|
JP2022507718A
(ja)
|
2018-11-20 |
2022-01-18 |
コーネル ユニバーシティー |
放射線核種の大環状錯体およびがんの放射線療法におけるそれらの使用
|
EP3887823B1
(en)
|
2018-11-28 |
2024-01-17 |
Institut National de la Santé et de la Recherche Médicale (INSERM) |
Methods and kit for assaying lytic potential of immune effector cells
|
KR20210100668A
(ko)
|
2018-12-06 |
2021-08-17 |
제넨테크, 인크. |
항-CD79b 면역접합체, 알킬화제 및 항-CD20 항체를 포함하는 미만성 큰 B-세포 림프종의 조합 요법
|
US20220018835A1
(en)
|
2018-12-07 |
2022-01-20 |
INSERM (Institut National de la Santé et de la Recherche Médicale |
Use of cd26 and cd39 as new phenotypic markers for assessing maturation of foxp3+ t cells and uses thereof for diagnostic purposes
|
JP2022511112A
(ja)
|
2018-12-11 |
2022-01-28 |
セラヴァンス バイオファーマ アール&ディー アイピー, エルエルシー |
Alk5阻害剤としてのナフチリジンおよびキノリン誘導体
|
WO2020127059A1
(en)
|
2018-12-17 |
2020-06-25 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Use of sulconazole as a furin inhibitor
|
KR20210121077A
(ko)
|
2019-01-15 |
2021-10-07 |
인쎄름 (엥스띠뛰 나씨오날 드 라 쌍떼 에 드 라 흐쉐르슈 메디깔) |
돌연변이된 인터루킨-34 (il-34) 폴리펩티드 및 요법에서의 이의 용도
|
WO2020169472A2
(en)
|
2019-02-18 |
2020-08-27 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods of inducing phenotypic changes in macrophages
|
CN113660953A
(zh)
|
2019-04-01 |
2021-11-16 |
豪夫迈·罗氏有限公司 |
用于稳定含蛋白质制剂的组合物和方法
|
JP2022527972A
(ja)
|
2019-04-02 |
2022-06-07 |
アンスティチュ ナショナル ドゥ ラ サンテ エ ドゥ ラ ルシェルシュ メディカル |
前悪性病変を有する患者において癌を予測及び予防する方法
|
WO2020208060A1
(en)
|
2019-04-09 |
2020-10-15 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Use of sk2 inhibitors in combination with immune checkpoint blockade therapy for the treatment of cancer
|
WO2020212484A1
(en)
|
2019-04-17 |
2020-10-22 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods and compositions for treatment of nlrp3 inflammasome mediated il-1beta dependent disorders
|
CA3138045C
(en)
|
2019-05-14 |
2024-02-20 |
Genentech, Inc. |
Methods of using anti-cd79b immunoconjugates to treat follicular lymphoma
|
JP2022539248A
(ja)
|
2019-07-02 |
2022-09-07 |
フレッド ハッチンソン キャンサー リサーチ センター |
組換えad35ベクター及び関連遺伝子治療改善
|
CN110551221B
(zh)
|
2019-07-02 |
2021-03-05 |
广州爱思迈生物医药科技有限公司 |
一种双特异性抗体及其制备方法与应用
|
WO2021024020A1
(en)
|
2019-08-06 |
2021-02-11 |
Astellas Pharma Inc. |
Combination therapy involving antibodies against claudin 18.2 and immune checkpoint inhibitors for treatment of cancer
|
AU2020336440A1
(en)
*
|
2019-08-30 |
2022-03-24 |
Qilu Puget Sound Biotherapeutics Corporation |
Anti-CD20 antibodies, anti-CD37 antibodies, and mixtures thereof
|
JP2022548848A
(ja)
|
2019-09-11 |
2022-11-22 |
ノバルティス アーゲー |
オファツムマブ治療患者における多発性硬化症以外の状態の管理
|
EP4230655A3
(en)
|
2019-09-11 |
2023-11-01 |
Novartis AG |
Treatment of rms by switching therapy
|
TW202118512A
(zh)
|
2019-09-12 |
2021-05-16 |
美商建南德克公司 |
治療狼瘡性腎炎之組成物及方法
|
WO2021058091A1
(en)
|
2019-09-24 |
2021-04-01 |
Biontech Rna Pharmaceuticals Gmbh |
Treatment involving therapeutic antibody and interleukin-2 (il2)
|
EP3800201A1
(en)
|
2019-10-01 |
2021-04-07 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Cd28h stimulation enhances nk cell killing activities
|
EP4037710A1
(en)
|
2019-10-04 |
2022-08-10 |
Institut National de la Santé et de la Recherche Médicale (INSERM) |
Methods and pharmaceutical composition for the treatment of ovarian cancer, breast cancer or pancreatic cancer
|
CN118557751A
(zh)
|
2019-10-18 |
2024-08-30 |
基因泰克公司 |
使用抗CD79b免疫缀合物治疗弥漫性大B细胞淋巴瘤的方法
|
US20220411529A1
(en)
|
2019-11-06 |
2022-12-29 |
Genmab B.V. |
Antibody variant combinations and uses thereof
|
JP2023502662A
(ja)
|
2019-11-22 |
2023-01-25 |
セラヴァンス バイオファーマ アール&ディー アイピー, エルエルシー |
Alk5阻害剤としての置換1,5-ナフチリジンまたはキノリン
|
CN111100204B
(zh)
*
|
2019-11-26 |
2022-03-11 |
山东立菲生物产业有限公司 |
靶向cd20的抗体、其制备方法和应用
|
WO2021119482A1
(en)
|
2019-12-13 |
2021-06-17 |
Progenity, Inc. |
Ingestible device for delivery of therapeutic agent to the gastrointestinal tract
|
US20220372162A1
(en)
*
|
2019-12-18 |
2022-11-24 |
TeneoFour, Inc. |
Pct/us2020/066088
|
CN115427814A
(zh)
|
2020-02-21 |
2022-12-02 |
根马布有限公司 |
用于定量糖蛋白的方法
|
WO2021203131A1
(en)
|
2020-03-31 |
2021-10-07 |
Theravance Biopharma R&D Ip, Llc |
Substituted pyrimidines and methods of use
|
US20230151106A1
(en)
|
2020-04-09 |
2023-05-18 |
Novartis Ag |
OFATUMUMAB FOR TREATING MS WHILE MAINTAINING SERUM IgG
|
JP2023522691A
(ja)
|
2020-04-21 |
2023-05-31 |
ユニバーシティ オブ ロチェスター |
ヒト精巣上体タンパク質4の阻害剤
|
JP2023524639A
(ja)
|
2020-04-22 |
2023-06-13 |
アイオバンス バイオセラピューティクス,インコーポレイテッド |
患者特異的免疫療法用細胞の製造調整システム及び調整方法
|
EP4139359A1
(en)
|
2020-04-24 |
2023-03-01 |
Genentech, Inc. |
Methods of using anti-cd79b immunoconjugates
|
CA3176436A1
(en)
|
2020-05-08 |
2021-11-11 |
Tahamtan Ahmadi |
Bispecific antibodies against cd3 and cd20
|
JP2023528071A
(ja)
|
2020-06-03 |
2023-07-03 |
エムヴィ バイオセラピューティクス エスエー |
Atp加水分解酵素と免疫チェックポイントモジュレーターとの組合せ、並びにその使用
|
EP4165041A1
(en)
|
2020-06-10 |
2023-04-19 |
Theravance Biopharma R&D IP, LLC |
Naphthyridine derivatives useful as alk5 inhibitors
|
WO2021260675A1
(en)
|
2020-06-24 |
2021-12-30 |
Yeda Research And Development Co. Ltd. |
Agents for sensitizing solid tumors to treatment
|
EP4178611A1
(en)
|
2020-07-07 |
2023-05-17 |
BioNTech SE |
Therapeutic rna for hpv-positive cancer
|
KR20230152783A
(ko)
|
2020-07-07 |
2023-11-03 |
칸큐어 엘엘씨 |
Mic 항체 및 결합제 및 이의 사용 방법
|
US20230295146A1
(en)
|
2020-07-24 |
2023-09-21 |
The University Of Rochester |
Inhibitors of interleukin-1 receptor-associated kinases 1 and 4
|
CN112062855B
(zh)
|
2020-08-26 |
2024-08-30 |
北京天诺健成医药科技有限公司 |
一种含有衔接器的药物治疗剂的开发和应用
|
WO2022043415A1
(en)
|
2020-08-27 |
2022-03-03 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods for detecting the presence of pemphigus-specific autoantibodies in a sample
|
CN116782933A
(zh)
|
2020-09-10 |
2023-09-19 |
健玛保 |
用于治疗弥漫性大b细胞淋巴瘤的联合疗法中的针对cd3和cd20的双特异性抗体
|
IL301086A
(en)
|
2020-09-10 |
2023-05-01 |
Genmab As |
Bispecific antibody against CD3 and CD20 in combination therapy for the treatment of follicular lymphoma
|
JP2023542290A
(ja)
|
2020-09-10 |
2023-10-06 |
ジェンマブ エー/エス |
濾胞性リンパ腫を治療するための併用療法におけるcd3及びcd20に対する二重特異性抗体
|
KR20230066583A
(ko)
|
2020-09-10 |
2023-05-16 |
젠맵 에이/에스 |
미만성 대 b-세포 림프종을 치료하기 위한 조합 요법에서의 cd3 및 cd20에 대한 이중특이적 항체
|
CA3190349A1
(en)
|
2020-09-10 |
2022-03-17 |
Brian Elliott |
Bispecific antibodies against cd3 and cd20 for treating chronic lymphocytic leukemia
|
US20230312759A1
(en)
|
2020-09-10 |
2023-10-05 |
Genmab A/S |
Bispecific antibody against cd3 and cd20 in combination therapy for treating diffuse large b-cell lymphoma
|
CN116547305A
(zh)
|
2020-11-11 |
2023-08-04 |
生物技术公司 |
针对程序性死亡-1蛋白的单克隆抗体及其在医学中的用途
|
WO2022130206A1
(en)
|
2020-12-16 |
2022-06-23 |
Pfizer Inc. |
TGFβr1 INHIBITOR COMBINATION THERAPIES
|
TW202245808A
(zh)
|
2020-12-21 |
2022-12-01 |
德商拜恩迪克公司 |
用於治療癌症之治療性rna
|
WO2022135667A1
(en)
|
2020-12-21 |
2022-06-30 |
BioNTech SE |
Therapeutic rna for treating cancer
|
WO2022135666A1
(en)
|
2020-12-21 |
2022-06-30 |
BioNTech SE |
Treatment schedule for cytokine proteins
|
IL304067A
(en)
|
2021-01-06 |
2023-08-01 |
Hoffmann La Roche |
Combined treatment using PD1-LAG3 bispecific antibody and CD20 T cell bispecific antibody
|
WO2022198192A1
(en)
|
2021-03-15 |
2022-09-22 |
Genentech, Inc. |
Compositions and methods of treating lupus nephritis
|
EP4314082A1
(en)
|
2021-03-24 |
2024-02-07 |
The United States of America, as represented by the Secretary, Department of Health and Human Services |
Bicistronic chimeric antigen receptors designed to reduce retroviral recombination and uses thereof
|
TW202304506A
(zh)
|
2021-03-25 |
2023-02-01 |
日商安斯泰來製藥公司 |
涉及抗claudin 18.2抗體的組合治療以治療癌症
|
JP2024511189A
(ja)
|
2021-03-26 |
2024-03-12 |
ビオンテック・ソシエタス・エウロパエア |
がんの処置における抗ca19-9抗体およびfolfirinoxを用いた組合せ療法。
|
JP2024518709A
(ja)
|
2021-04-10 |
2024-05-02 |
プロファウンドバイオ ユーエス カンパニー |
Folr1結合剤、そのコンジュゲートおよびこれを使用する方法
|
CA3216479A1
(en)
|
2021-04-14 |
2022-10-20 |
Novartis Ag |
Ofatumumab for treating multiple sclerosis in asian patients
|
TW202308699A
(zh)
|
2021-04-23 |
2023-03-01 |
美商普方生物製藥美國公司 |
Cd70結合劑、其結合物及其使用方法
|
US20240207304A1
(en)
|
2021-04-28 |
2024-06-27 |
Mina Therapeutics Limited |
Combination Therapies Comprising C/EBP Alpha saRNA
|
WO2022228705A1
(en)
|
2021-04-30 |
2022-11-03 |
F. Hoffmann-La Roche Ag |
Dosing for combination treatment with anti-cd20/anti-cd3 bispecific antibody and anti-cd79b antibody drug conjugate
|
IL307821A
(en)
|
2021-04-30 |
2023-12-01 |
Hoffmann La Roche |
Dosage for treatment with BISPIFIC ANTI-CD20/ANTI-CD3 antibody
|
EP4333987A1
(en)
|
2021-05-07 |
2024-03-13 |
Viela Bio, Inc. |
Use of an anti-cd19 antibody to treat myasthenia gravis
|
CN117396232A
(zh)
|
2021-05-12 |
2024-01-12 |
基因泰克公司 |
使用抗cd79b免疫缀合物治疗弥漫性大b细胞淋巴瘤的方法
|
WO2022251359A1
(en)
|
2021-05-26 |
2022-12-01 |
Theravance Biopharma R&D Ip, Llc |
Bicyclic inhibitors of alk5 and methods of use
|
WO2022253756A1
(en)
|
2021-06-01 |
2022-12-08 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Use of b cell depleting agents for the treatment of rheumatic heart disease
|
KR20240049794A
(ko)
|
2021-06-07 |
2024-04-17 |
프로비던스 헬스 앤드 서비시즈 - 오레곤 |
Cxcr5, pd-1, 및 icos 발현 종양 반응성 cd4 t 세포 및 그의 용도
|
WO2022262959A1
(en)
|
2021-06-15 |
2022-12-22 |
Astellas Pharma Europe Bv |
Bispecific binding agents binding to cldn18.2 and cd3
|
CA3220318A1
(en)
|
2021-06-17 |
2022-12-22 |
Glaxosmithkline Intellectual Property Limited |
Anti-baff antibodies for use in a method of treatment of long covid and/or post-acute sequelae sars-cov-2 infection (pasc)
|
EP4367269A1
(en)
|
2021-07-05 |
2024-05-15 |
Inserm (Institut National De La Sante Et De La Recherche Medicale) |
Gene signatures for predicting survival time in patients suffering from renal cell carcinoma
|
KR20240046323A
(ko)
|
2021-07-13 |
2024-04-08 |
비온테크 에스이 |
암에 대한 병용 요법에 있어서 cd40 및 cd137에 대한 다중특이 결합제
|
US20240336697A1
(en)
|
2021-08-07 |
2024-10-10 |
Genentech, Inc. |
Methods of using anti-cd79b immunoconjugates to treat diffuse large b-cell lymphoma
|
EP4387999A1
(en)
|
2021-08-16 |
2024-06-26 |
Novartis AG |
Ofatumumab for treating pediatric ms
|
TW202333802A
(zh)
|
2021-10-11 |
2023-09-01 |
德商拜恩迪克公司 |
用於肺癌之治療性rna(二)
|
CA3238167A1
(en)
|
2021-11-19 |
2023-05-25 |
Maria Leia Smith |
Gpc3 binding agents, conjugates thereof and methods of using the same
|
IL314344A
(en)
|
2022-01-28 |
2024-09-01 |
Genmab As |
Bispecific antibodies against CD3 and CD20 in combination therapy for the treatment of diffuse large B-cell lymphoma
|
WO2023144306A1
(en)
|
2022-01-28 |
2023-08-03 |
Genmab A/S |
Bispecific antibody against cd3 and cd20 in combination therapy for treating diffuse large b-cell lymphoma
|
US20230414750A1
(en)
|
2022-03-23 |
2023-12-28 |
Hoffmann-La Roche Inc. |
Combination treatment of an anti-cd20/anti-cd3 bispecific antibody and chemotherapy
|
WO2023198839A2
(en)
|
2022-04-13 |
2023-10-19 |
Genmab A/S |
Bispecific antibodies against cd3 and cd20
|
WO2023198727A1
(en)
|
2022-04-13 |
2023-10-19 |
F. Hoffmann-La Roche Ag |
Pharmaceutical compositions of anti-cd20/anti-cd3 bispecific antibodies and methods of use
|
WO2023201369A1
(en)
|
2022-04-15 |
2023-10-19 |
Iovance Biotherapeutics, Inc. |
Til expansion processes using specific cytokine combinations and/or akti treatment
|
WO2023217987A1
(en)
|
2022-05-12 |
2023-11-16 |
BioNTech SE |
Monoclonal antibodies directed against programmed death-1 protein and their use in medicine
|
CN116162153B
(zh)
*
|
2022-09-01 |
2024-09-10 |
复旦大学附属中山医院 |
一种乙肝病毒表面抗原的单克隆抗体及其应用
|
WO2024052356A1
(en)
|
2022-09-06 |
2024-03-14 |
Institut National de la Santé et de la Recherche Médicale |
Inhibitors of the ceramide metabolic pathway for overcoming immunotherapy resistance in cancer
|
US20240174761A1
(en)
|
2022-11-02 |
2024-05-30 |
Genmab A/S |
Bispecific antibodies against cd3 and cd20 for treating richter's syndrome
|
WO2024094741A1
(en)
|
2022-11-03 |
2024-05-10 |
F. Hoffmann-La Roche Ag |
Combination therapy with anti-cd19/anti-cd28 bispecific antibody
|
WO2024102734A1
(en)
|
2022-11-08 |
2024-05-16 |
Genentech, Inc. |
Compositions and methods of treating childhood onset idiopathic nephrotic syndrome
|
WO2024112571A2
(en)
|
2022-11-21 |
2024-05-30 |
Iovance Biotherapeutics, Inc. |
Two-dimensional processes for the expansion of tumor infiltrating lymphocytes and therapies therefrom
|
WO2024126457A1
(en)
|
2022-12-14 |
2024-06-20 |
Astellas Pharma Europe Bv |
Combination therapy involving bispecific binding agents binding to cldn18.2 and cd3 and immune checkpoint inhibitors
|
WO2024153636A1
(en)
|
2023-01-17 |
2024-07-25 |
Institut National de la Santé et de la Recherche Médicale |
Vasorin as a biomarker and biotarget in nephrology
|
WO2024173607A2
(en)
|
2023-02-14 |
2024-08-22 |
Evolveimmune Therapeutics, Inc. |
Combination of bispecific antibodies and chimeric antigen receptor t cells for treatment
|
US20240285762A1
(en)
|
2023-02-28 |
2024-08-29 |
Juno Therapeutics, Inc. |
Cell therapy for treating systemic autoimmune diseases
|